Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 23 Jul 2014 |
| Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma | 18 Jul 2014 |
| Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen | 14 Jul 2014 |
| Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen | 7 Jul 2014 |